Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

Research, Funding and Drug Development Resources:

ACS CAN submitted comments to Medicare Administrative Contractors proposing coverage for minimal residual disease testing for cancer. 

Precision medicine in cancer involves targeted therapies which work by interfering with specific cellular processes involved in the growth, spread, and progression of cancer. Treatment with targeted therapy often requires diagnostic testing to identify specific cancer biomarkers. Testing patients for biomarkers is integral to precision medicine in cancer care.

Every five years the FDA drug user fees are reauthorized, offering an opportunity to influence priorities.  ACS CAN is recommending an increased focus on patient representation in regulatory decision making, guidance to drive increased use of decentralized trials, and a scientific focus on dispar

Advances in precision medicine have led to targeted cancer therapies that have improved patient outcomes and quality of life within populations of cancer patients with very specific biomarkers. Testing patients for cancer biomarkers is integral to identify those who may benefit from targeted therapy. Despite the importance of such testing, many cancer patients are not tested for biomarkers. This fact sheet highlights recent advancements in targeted cancer therapies and data from ACS CAN Survivor Views surveys of cancer patients and survivors assessing barriers to biomarker testing.  

The U.S. Food and Drug Administration's (FDA's) typically follows a standard review process to evaluate a drug’s safety and efficacy. However, drug therapies that address unmet medical needs, treat serious or life-threatening conditions, or show a significant advantage over current therapies may be eligible for one or more of FDA’s four Expedited Review Programs. This factsheet describes those programs.  

A significant portion of the U.S. Food and Drug Administration's (FDA's) operating budget comes from user fees paid by industry.  The authority to collect these fees expires every five years and must be renewed.  This factsheet describes the program.  

In response to's request for information to guide their modernization process, ACS CAN, along with 14 other organizations, submitted extensive comments.  The suggestions were derived from multi-stakeholder collaborations underway over the past year and reflect consensus ideas a

In response to a request from FDA, ACS CAN has provided recommendations for areas of focus for the Office of Minority Health and Health Equity (OMHHE).  Recommendations include assessing the applicability of drug "snapshot" data, evaluating the appropriateness of aggregating racial groups for ana

In response to a request from Reps. Upton and DeGette for ideas to include in Cures 2.0 legislation, ACS CAN and six other organization urged the representatives to consider the recommendations for overcoming barriers to clinical trial participation published as part of a recent landscape report.